Nicholas Philip Van Der Meulen

Title: Innovations of Nicholas Philip Van Der Meulen

Introduction

Nicholas Philip Van Der Meulen is a notable inventor based in Schinznach-Dorf, Switzerland. He has made significant contributions to the field of radiopharmaceuticals, holding 2 patents that focus on advanced medical applications. His work is particularly relevant in the treatment of tumor diseases and the production of radionuclides for imaging purposes.

Latest Patents

One of his latest patents involves the development of a radiopeptide that includes a radionuclide, specifically terbium-161. This radiopeptide is designed to be a somatostatin receptor antagonist, making it suitable for treating tumor diseases. Another significant patent focuses on the production of the radionuclide Scandium-43, which is essential for positron emission tomography. This method utilizes a solid target with an isotopically enriched layer, irradiated with a charged-particle beam to achieve commercially significant yields.

Career Highlights

Throughout his career, Nicholas has worked with esteemed institutions such as the Paul Scherrer Institute and the University of Basel. His research has contributed to advancements in medical imaging and cancer treatment, showcasing his expertise in the field of radiopharmaceuticals.

Collaborations

Nicholas has collaborated with notable colleagues, including Cristina Müller and Roger Schibli. These partnerships have further enhanced his research and development efforts in the field.

Conclusion

Nicholas Philip Van Der Meulen's innovative work in radiopharmaceuticals and his contributions to medical technology highlight his importance as an inventor. His patents reflect a commitment to advancing healthcare solutions, particularly in the treatment of cancer.